Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma

NCT04530006 is registered in ClinicalTrials.gov with CancerCare Manitoba as lead sponsor.

NCT NCT04530006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04530006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma
Lead sponsor
CancerCare Manitoba
Phase
Not applicable
Overall status
Unknown status
Start date
December 2, 2020
Completion date
August 31, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme